Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824276 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1SGPL1FDPSDNM1 | |
| SCHEMBL27747000 | 0.86 | — | — | |
| SCHEMBL16180731 | 0.82 | SGPL1 (0.40) | SGPL1FDPSDNM1OPRM1 | |
| SCHEMBL23038325 | 0.82 | SGPL1 (0.33) | ALDH1A1TDP1SGPL1FDPSDNM1 | |
| SCHEMBL16358397 | 0.80 | SGPL1 (0.42) | SGPL1FDPSDNM1OPRM1 | |
| SCHEMBL14848265 | 0.77 | SGPL1 (0.44) | SGPL1FDPSDNM1OPRM1 | |
| SCHEMBL13637149 | 0.77 | SGPL1 (0.44) | SGPL1FDPSDNM1OPRM1 | |
| SCHEMBL28664154 | 0.77 | SGPL1 (0.44) | SGPL1FDPSDNM1OPRM1 | |
| Hydrochloric Acid SCHEMBL29224660 | 0.76 | — | — | |
| SCHEMBL23038570 | 0.76 | SGPL1 (0.39) | SGPL1FDPSDNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550481-B2 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, APP | ALDH1A1 1506/4885TDP1 263/4885SGPL1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.